TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of “Moderate Buy” by Brokerages

TG Therapeutics, Inc. (NASDAQ:TGTX) has earned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $40.67.

A number of brokerages have issued reports on TGTX. The Goldman Sachs Group lifted their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. StockNews.com downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, December 22nd. HC Wainwright increased their target price on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. TD Cowen began coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target for the company. Finally, JPMorgan Chase & Co. increased their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th.

Insider Transactions at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the transaction, the director now owns 100,195 shares of the company’s stock, valued at $3,049,935.80. This represents a 4.75 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

A number of institutional investors have recently bought and sold shares of TGTX. State Street Corp raised its stake in TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after purchasing an additional 2,398,015 shares during the period. Marshall Wace LLP acquired a new stake in shares of TG Therapeutics during the 2nd quarter worth $36,501,000. Hood River Capital Management LLC raised its position in shares of TG Therapeutics by 6.7% in the 2nd quarter. Hood River Capital Management LLC now owns 1,572,929 shares of the biopharmaceutical company’s stock worth $27,982,000 after buying an additional 98,892 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of TG Therapeutics by 0.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,184,609 shares of the biopharmaceutical company’s stock worth $27,708,000 after buying an additional 7,939 shares during the period. Finally, Principal Financial Group Inc. boosted its holdings in TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after acquiring an additional 725,371 shares during the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Stock Performance

TGTX opened at $33.50 on Friday. The stock’s 50 day simple moving average is $30.31 and its 200 day simple moving average is $24.36. The stock has a market cap of $5.21 billion, a P/E ratio of -334.97 and a beta of 2.25. TG Therapeutics has a 1-year low of $12.84 and a 1-year high of $36.84. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm’s revenue for the quarter was down 49.4% on a year-over-year basis. During the same period last year, the company posted $0.73 EPS. As a group, equities analysts anticipate that TG Therapeutics will post 0.17 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.